Scancell (LON:SCLP) Issues Earnings Results

Scancell (LON:SCLPGet Free Report) posted its quarterly earnings results on Thursday. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Scancell Stock Performance

Shares of SCLP stock opened at GBX 9.40 ($0.12) on Friday. The stock has a fifty day moving average price of GBX 10.84 and a 200 day moving average price of GBX 13.63. The company has a debt-to-equity ratio of 61.41, a quick ratio of 13.01 and a current ratio of 3.42. The stock has a market cap of £87.38 million, a PE ratio of -940.00 and a beta of 0.35. Scancell has a 1 year low of GBX 8.60 ($0.11) and a 1 year high of GBX 19.75 ($0.24).

About Scancell

(Get Free Report)

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

See Also

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.